Track Finch Therapeutics Group's long-term debt ($27M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2024), FNCH shows a long-term debt of $27M. That compares with $29M in the prior-year period — down 8.5% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, FNCH's long-term debt is now $27M (was $29M) — a 8.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Finch Therapeutics Group is outperforming or lagging.
Tracking FNCH's long-term debt over time shows whether Finch Therapeutics Group is scaling, shrinking, or reshaping that part of the business. The current reading is $27M That compares with $29M in the prior-year period — down 8.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Finch Therapeutics Group's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $27M) with ownership activity and broader fundamentals.
Finch Therapeutics Group's long-term debt is $27M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.